News

October 24, 2016October 24, 2016

FDA Approves Tecentriq Immunotherapy for Specific Type of Advanced Lung Cancer

Lung Cancer, News

The U.S. Food and Drug Administration (FDA) approved Genentech’s Tecentriq (atezolizumab) as a treatment for people with metastatic non-small cell lung cancer (NSCLC). The drug is specifically indicated for NSCLC patients whose ... Read more

October 21, 2016October 21, 2016

NIH Awards Scientists $5.2M for Lung Regeneration Research

Asthma, Cystic Fibrosis, News

Researchers at the University of Pennsyvania School of Medicine, Cincinnati Children’s Hospital and Boston University were awarded a seven-year, $5.2 million grant to study mechanisms that promote lung regeneration. The grant is from ... Read more

October 20, 2016October 20, 2016

#CHEST2016 – Bayer to Present New Data on PAH and Bronchiectasis Therapies

Bronchiectasis, News, Pulmonary Hypertension

Bayer announced it will be giving three oral presentations on lead investigative therapies Adempas (riociguat) for the treatment of pulmonary arterial hypertension (PAH), and ciprofloxacin DPI (dry powder for inhalation) to treat non-cystic ... Read more

October 19, 2016October 19, 2016

Researcher Awarded $13.3M Federal Grant to Test Novel Treatments for Cystic Fibrosis, Severe Asthma

Asthma, Cystic Fibrosis, News

A researcher at Case Western Reserve University (CWRU) in Cleveland, Ohio, was awarded a five-year, $13.3 million federal grant to fund the development and testing of personalized medication combinations tailored to ... Read more

October 18, 2016October 18, 2016

Tecentriq for Lung Cancer Outperforms Conventional Chemotherapy, Increases Survival in Phase 3 Study

News

Genentech recently announced positive results from the pivotal Phase 3 OAK study (NCT02008227) demonstrating that its cancer immunotherapy Tecentriq (atezolizumab) is more effective than the chemotherapy Taxotere for increasing patients’ median overall survival. The findings were presented at ... Read more

October 17, 2016October 17, 2016

FDA Will Review New Drug Application for SUN-101/eFlow for COPD Treatment

News

The U.S. Food and Drug Administration (FDA) has accepted for review Sunovion’s new drug application (NDA) for its SUN-101/eFlow system as a long-term maintenance therapy for airflow obstruction in adults with chronic obstructive pulmonary ... Read more

October 14, 2016October 14, 2016

Pivotal Clinical Trial of Zephyr Endobronchial Valve for Emphysema Completes Enrollment

News

Pulmonx announced that patient enrollment is complete for its pivotal investigational device exemption (IDE) study of the Zephyr Endobronchial Valve (EBV) for the treatment of severe emphysema. Results from the randomized, multi-center LIBERATE clinical ... Read more

October 13, 2016October 13, 2016

Aradigm Partners to Develop Treatments for Resistant Biofilm Lung Infections

Bronchiectasis, Cystic Fibrosis, News

Aradigm Corporation is collaborating with the University of Sydney in Australia to develop nanotechnologies targeting fungal and bacterial biofilms, a common complication of infections associated with chronic diseases like cystic fibrosis ... Read more

October 12, 2016October 12, 2016

Insmed Reaches Agreement with AstraZeneca for Potential Bronchiectasis Therapy

Bronchiectasis, News

Insmed Incorporated, a biopharmaceutical company focused on rare diseases, disclosed a licensing agreement with AstraZeneca for global exclusive rights to AZD7986, a new oral, reversible inhibitor of dipeptidyl peptidase I (DPP1, aka ... Read more

October 11, 2016October 11, 2016

First Patient Enrolled in Phase 3 Trial Assessing Bardoxolone Methyl to Treat CTD-PAH

News, Pulmonary Hypertension

Reata Pharmaceuticals announced the enrollment of the first patient in its Phase 3 CATALYST study (NCT02657356) that will evaluate the effectiveness and safety of bardoxolone methyl in patients with connective ... Read more